No Data
No Data
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Roche Obesity-pill Trial Results Weigh on Shares of Eli Lilly, Novo Nordisk
Shares of weight-loss drugmakers including Eli Lilly & Co., Novo Nordisk A/S and Structure Therapeutics Inc. fell on Wednesday after Roche Holding AG announced positive early-stage trial data for its experimental obesity pill.
Altimmune (NASDAQ:ALT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, Altimmune (NASDAQ:ALT) shareholders have done very
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating
B.Riley Financial analyst Mayank Mamtani maintains $Altimmune(ALT.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 27.8% and a total average return of -16.5% over
These Are the Weight Loss Drug Stocks With the Most Upside - SA Sentiment Survey
This Weight Loss Stock Is the Best Alternative to Eli Lilly, Novo - SA Sentiment
No Data
Chili Dog : So see how many
DazzyJazzy : buying ang waiting